Table 1.
Clinical parameters of seven laryngeal cancer patients that underwent lncRNA expression profiling.
Figure 1.
Hierarchical clustering results of lncRNA expression profiles in LSCC samples and adjacent normal tissue.
Distinct differences were observed between LSCC tissue and adjacent non-tumorous tissue. “A”, tumor group; and “B”, normal group.
Figure 2.
Volcano plot filtering map depicting differentially expressed lncRNAs.
Red points represent differentially expressed lncRNAs with statistical significance (P<0.05). A and B represent cancer and normal, respectively.
Table 2.
Differentially expressed lncRNAs in LSCC tissue compared with adjacent non-tumorous tissue.
Figure 3.
The expression of AC026166.2-001 by quantitative RT-PCR assay.
(A) Sequencing results of AC026166.2-001. (B) Expression levels of AC026166.2-001 in LSCC tumor, adjacent normal samples (n = 87) and metastatic neck lymph nodes samples (n = 34). Real-time qRT-PCR was performed to determine the expression levels of AC026166.2-001. AC026166.2-001 levels were significantly lower in tumor tissues than in corresponding non-tumorous tissues (n = 87, P<0.001). (C) AC026166.2-001 expression was significantly lower in metastatic neck lymph nodes compared with matched tumor tissues (n = 34, P<0.05).
Table 3.
Relationship between AC026166.2-001 or RP11-169D4.1-001 levels (ΔCt) and clinicopathological features of laryngeal cancer patients.
Figure 4.
The expression of RP11-169D4.1-001 by quantitative RT-PCR assay.
(A) RP11-169D4.1-001 expression levels in LSCC tumor, adjacent normal samples (n = 87) and metastatic neck lymph nodes samples (n = 34). Real-time qRT-PCR was employed to determine RP11-169D4.1-001 expression. RP11-169D4.1-001 levels were significantly lower in tumor tissues than in corresponding non-tumorous tissues (n = 87, P<0.001). (B) RP11-169D4.1-001 expression was significantly lower in metastatic neck lymph nodes compared with matched tumor tissues (n = 34, P<0.05). (C) Sequencing results for RP11-169D4.1-001.
Figure 5.
Survival curve of laryngeal carcinoma patients.
(A) Survival curve of laryngeal carcinoma patients with varying expression levels of AC026166.2-001 (P = 0.029). Lower curve: LSCC patients with low expression (n = 63); upper curve: LSCC patients with high expression (n = 24). (B) Survival curves of laryngeal carcinoma patients (n = 87) with differing. RP11-169D4.1-001 expression levels (P = 0.025). Lower curve: LSCC patients with low expression (n = 47); upper curve: LSCC patients with high expression (n = 30). (C) Survival curves of laryngeal carcinoma patients according to T stage (P<0.001). (D) Survival curves of laryngeal carcinoma patients with and without cervical lymph node metastasis (P<0.001). (E) Survival curves of laryngeal carcinoma patients according to histological differentiation (P = 0.182).
Figure 6.
A represents AC026166.2-001, B represents RP11-169D4.1-001.